References in the content below refer to the PBMEF Guide.
Definitions
Number of people with drug-resistant (DR) TB (rifampicin-resistant [RR] and multidrug-resistant [MDR] TB and pre-extensively drug-resistant [pre-XDR] and extensively drug-resistant [XDR] TB) who initiated “all oral” longer treatment regimen during the reporting period.
“Longer treatment regimens” refer to regimens with a duration of 14 months or more, usually lasting 18–24 months.
Numerator
Denominator
Ref # |
TX_LTR_ENROLL
(Previously RN-8) |
Tier Level |
Core Plus Indicator
|
Category |
Cure
|
Type |
Outcome
|
Unit of Measure |
Number of people
|
Data Type |
Integer
|
Disaggregations |
Age (<15, 15+)
Sex
|
Reporting Level |
All Core Plus indicators should be reported at the national level; data may also be collected subnationally for more granular monitoring.
|
Reporting Frequency |
This indicator should be reported on a semiannual basis at a minimum. More frequent monitoring on a quarterly basis is recommended.
|
The data sources are basic management unit TB register, RR/MDR-TB register, and electronic management information systems at the health facility and district levels. This standard World Health Organization (WHO) indicator can also be calculated using the WHO Global TB Programme database variable: mdrxdr_alloral_tx.
This indicator provides important information for monitoring initiation of people with DR-TB on all oral longer course regimens. The WHO consolidated guidelines on DR-TB treatment signal an important departure from previous approaches to treat DR-TB, recommending fully oral regimens to be prioritized and to be the preferred option for most patients. Many countries have adopted this approach as their national policy.
These data are valuable for monitoring initiation of people diagnosed with DR-TB on all oral longer treatment and for planning procurement of second-line drugs (SLDs).
This indicator can be used to track progress in achieving high rates of all oral longer treatment regimen use for people diagnosed with DR-TB. It is helpful to guide programmatic decisions for scale up of treatment for DR-TB. This indicator can be compared with the number of people with DR-TB who were initiated on treatment, and the number of people with DR-TB initiated on “all oral” shorter treatment regimens. It can be presented and visualized using tables, charts, line graphs, etc.
Indicator Visualizations
We do not currently have an indicator visualization for this indicator. Please check back later.